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Glycoproteins are formed through covalent linkages of
sugar residues to specific amino acids in proteins. Both
amide and acyl linkages are possible, and the resultant N-
glycosylated and O-glycosylated proteins carry remarkable
complexity in their oligosaccharide chains. N- and
O-glycosylations occur in proteins that remain in the
endoplasmic reticulum, proteins in the plasma membrane,
and proteins secreted into the extracellular surface. N-
glycosylation is localized to Asn residues, in the consensus
tripeptide sequence Asn-X-Ser/Thr (X is any amino acid
except proline). O-glycosylation of proteins occurs common-
ly on both Ser and Thr residues, as well as posttranslational
hydroxylation-created 5-hydroxylysine and 4-hydroxyproline
side chains. There are reports of glycosylation to Cys
residues. O-linked β-N-acetylglucosamine (O-GlcNAc) is a
modification of serine or threonine side chains of nuclear and
cytoplasmic proteins [1].
The study of glycoproteins began a very long time ago;
progress in understanding their structure and function has
awaited the development of methods for the isolation of
glycoproteins and glycans and the analysis of the sequences
of residues in both polysaccharides and polypeptides. The
field of “glycoproteomics” has emerged recently from the
global analyses of structures and functions of glycoproteins,
similar to the approaches now used in “proteomics.” The
questions we ask in glycoproteomics include: (1) what
glycoproteins are expressed in a cell type or tissue, (2) what
particular glycan structures of a glycoprotein is modified,
(3) which amino acid of a specific glycan structure is
attached to the backbond of a glycoprotein, (4) how the
function of a protein is modified by the specific glycosyl-
ation, (5) how abundant the glycoproteins and glycans are
in different conditions, and (6) whether a specific glyco-
sylation of a glycoprotein is associated with diseases that
can be used for diagnosis, prognosis, or treatment purposes.
Investigations of these questions in the glycoproteomics
field are hampered by the fact that there are no simple and
sensitive tools for efficient glycoprotein isolation, detection,
and quantification and we lack methods to analyze the
gycosylation sites of large number of glycoproteins.
The renewed interest in glycoproteomics has been initiated
by the completion of the human genome project, new
technological breakthroughs in mass spectrometry (MS)
instrumentation, and proteomic methods that have been
developed in the last decade. Recently, there has been
considerable progress in the development of methodologies
for elucidating the structures and functions of glycoproteins,
which has provided the opportunities to advance glycoprotein
analysis. The availability of affinity reagents for glycoproteins
(lectins and antibodies) [2] and newly developed glycopro-
tein derivatization and enrichment approaches [2–4] have
provided important breakthroughs. Application of these
glycoproteomic technologies may facilitate our understand-
ing of the perturbed glycosylation in disease progression and
could be used to discover glycoproteins as biomarkers or
therapeutic targets to improve disease diagnosis, prognosis,
or treatment outcomes.
In this first special edition of Glycoproteomics, we have
received excellent contributions from several experts in this
field. These papers cover different areas of glycoproteomics,
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including reviews of the existing methods of glycoproteo-
mics, new technology developments, and applications. The
articles are now published in two special issues due to the
large numbers of excellent manuscripts received. The first
issue includes six papers that describe innovative approaches
to analyze glycoprotein sequences or glycan structures. The
other issue includes five papers that describe the applications
of glycoproteomic technologies.
New techniques for glycoproteomic analysis, including
those for glycoprotein derivatization and enrichment, have
provided significant opportunities in glycoproteomic anal-
ysis [2–4]. The O-GlcNAc modification of proteins was
originally discovered in Gerald Hart’s laboratory over two
decades ago, and in this special issue of Glycoproteomics,
Wang and Hart review the methods and the recently
developed technologies for specific enrichment and detec-
tion of O-GlcNAc sites and their quantification [5]. Kaji
and Isobe summarize MS-based glycoproteomic technolo-
gies, with a special focus on preproteomic analysis
enrichment of glycopeptides from complex biological
mixtures and their assignments and structural analysis by
MS [6]. The methods include: (1) affinity chromatography
for capturing glycopeptides using lectins, antibodies, or
glycoprotein receptors that bind to certain glycans [2]; (2)
chemical coupling to capture glycopeptides to solid phase
[3, 4]; (3) carbohydrate tags via metabolic or chemo-
enzymatic labeling [7, 8]; and (4) liquid chromatography
(LC)-based enrichment of glycopeptides using hydrophilic
interaction, size exclusion chromatography, boronic acid,
strong cation exchange, and titanium dioxide [9–13]. Their
review also describes the mass spectrometric methods for
glycopeptide analysis and quantitative aspects of glycopro-
teomics. In addition to summarizing the existing methods
for glycoproteomics in this special edition, Lewandrowski
et al. describe a novel approach for glycopeptide enrich-
ment by electrostatic repulsion hydrophilic interaction
chromatography to separate glycopeptides from the bulk
of nonmodified peptides. The eluted glycopeptides were
then identified by tandem MS [14].
Given the number and diversity of glycans, there is a
need for new technologies that can more rapidly provide
differential carbohydrate–protein structural information on
a large scale. These new technologies are expected to
facilitate the rapid and sensitive identification of novel
biomarkers based on carbohydrate changes in glycoproteins
and lead to a better understanding of the connections of
glycan function in cellular mechanisms of health and
disease. In this special edition, Ralin et al. describe a new
microarray platform based on a Label Free Internal
Reflection Ellipsometry (LFIRE™) technique [15]. This
microarray platform allows simultaneous detection of
multiple glycoprotein–lectin interactions without the need
for reporter labels, while still providing high-throughput
kinetic screening of carbohydrate–lectin recognition at
much lower cost. The lectin immobilization format was
also used to demonstrate improved selectivity, specificity,
and increased functional avidity using multilectin affinity
chromatography to capture glycoproteins from biological
samples. Vakhrushev et al. describe a novel approach using
ion mobility tandem MS for the analysis of human
glycourinome to obtain carbohydrate pattern data of a
patient with congenital disorders of glycosylation (CDG)
[16].
Currently, 19 protein biomarkers are approved by the US
Food and Drug Administration in serum, urine, and tissue
and all are glycoproteins [17]. Prostate-specific antigen
(PSA) is the only tumor marker that is approved as
diagnostic marker, and others are intended for monitoring
response to therapy due to their low specificity for
screening purposes. To improve the specificity and obtain
precise and consistent analytical results, Li et al. analyzed
five clinically used tumor markers, including PSA, carci-
noembryonic antigen, Her-2, human chorionic gonadotro-
pin, and CA125, and provided a list of tryptic peptides and
glycopeptides as proteotypic peptides [18]. Heavy-isotope-
labeled-peptide standards could be synthesized based upon
the peptide sequences identified here and used for the
development of assays for these tumor markers using MS-
based methods. Using the targeted MS-based approach,
different glycoforms and isoforms of the glycoproteins can
be distinguished and specifically analyzed from the inter-
ference of other proteins in a complex biological mixture.
This will allow the investigation of the potential for
glycosylation patterns of these glycoproteins to be used as
markers for improved cancer detection.
Glycosylation changes in glycoproteins have been
identified in various diseases, such as CDGs and cancers,
and can be used as biomarkers for disease diagnosis or
prognosis [19, 20]. There has been an increasing effort in
applying glycoproteomic technologies to identify additional
disease biomarkers from specific organs or detection of
glycoproteins from a specific organ in body fluids. In the
second issue of this special edition of Glycoproteomics, five
papers were contributed to describe the application of
glycoproteomic technologies to biomarker discovery. The
paper by Kam and Poon provides an overview of the
historical applications of glycan analyses to biomarker
discovery [21]. In the past few years, attempts have been
made to develop novel methodologies to identify potential
glycobiomarkers, and plasma has been the focus of testing
different technologies for the identification of biomarkers
due to its ready accessibility. However, it is not clear if
direct proteomic analysis of plasma can be used to discover
new marker proteins that are associated with tumor
progression. Tian et al. reported that such tumor-specific
proteins can be detected in plasma in a chemically induced
2 Clin Proteom (2008) 4:1–4
skin cancer mouse model [22]. They analyzed glycopro-
teins from normal skin, benign papillomas, and malignant
carcinomas from mice using a recently developed platform,
solid-phase extraction of glycopeptides (SPEG) and MS,
and they identified glycoproteins preferentially expressed in
skin cancer, which include most known extracellular
proteins that have been reported to play roles in skin cancer
development. They further investigated whether these
tumor proteins could be detected in plasma from tumor-
bearing mice using isotope labeling and 2D-LC–matrix-
assisted laser desorption ionization–MS/MS. This result
indicates that direct proteomic analysis of tumors and
plasma using glycopeptide capture, isotopic labeling, and
MS can be used to discover new cancer-derived proteins in
plasma for early cancer detection. To identify changes in
the glycoproteins from serum that could be used as
biomarkers, Letarte et al. demonstrated a proof-of-concept
for the use of label-free quantitative glycoproteomics for a
biomarker discovery workflow [23]. Formerly, N-linked
glycopeptides were isolated from plasma proteins of mouse
model for skin cancer with a mutation in the p19ARF gene
using SPEG, and the glycopeptides were used for LC-MS
analyses. The computational framework, Corra, was then
used to determine the most discriminating peptide features
from cancer and control mice for their identification by
tandem MS using inclusion lists. The identified proteins
were assessed to determine the specific biological processes
that correlate with the presence of disease.
In addition to plasma, other body fluids or tissues are
also good sources for biomarker discovery of a specific
disease. Saliva is a body fluid that holds promise for use as
a diagnostic fluid. Ramachandran et al. employed SPEG to
enrich for formerly N-linked glycopeptides for analysis
using LC-tandem MS to identify the salivary N-glycopro-
teins [24]. N-glycoproteins from whole saliva, parotid fluid,
submandibular fluid, and sublingual fluid were identified
and compared in order to identify glycoproteins that are
differentially found in submandibular and sublingual
glandular secretions. The majority of the N-glycoproteins
were annotated as extracellular proteins. The identifying
glycoproteins in saliva may be valuable for future disease
biomarker studies. Chaerkady et al. carried out tissue
glycoproteomic profiling of tumor and adjacent non-cancer
liver tissues from hepatocellular carcinoma (HCC) patients
[25]. Glycoproteins enriched from liver samples using
lectin affinity chromatography and subsequent 18O/16O
labeling of peptides were used to obtain relative abundance
levels of lectin-bound proteins. Western blotting and
immunohistochemical staining were carried out for several
proteins to confirm MS results. As a complementary
approach, they also examined the relative expression of
proteins in HCC without glycoprotein enrichment. Lectin
affinity enrichment was found to be advantageous to
quantitate several interesting proteins, which were not
detected in the whole proteome screening approach.
We are very grateful to the positive responses from
researchers in the field of glycobiology and glycoproteo-
mics for their suggestions, support, contributions, and
reviewing of the manuscripts, which have made the first
special edition of Glycoproteomics possible. We would also
extend our gratitude to the editor-in-chief, reviewers, and
staffs from Clinical Proteomics and Springer for their
support of these special issues.
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